Log In
BCIQ
Print this Print this
 

glecaprevir (ABT-493)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionNext-generation HCV NS3/4A protease inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection; Treat chronic HCV genotype 1, 2, 4, 5 or 6 infection; Treat chronic HCV genotype 2 infection; Treat chronic HCV genotype 3 infection; Treat chronic HCV genotype 4, 5 or 6 infection; Treat chronic HCV genotypes 1 and 4-6 infection in patients who failed a prior direct-acting antiviral (DAA)-containing therapy; Treat chronic HCV genotypes 2 and 3 infection; Treat chronic HCV infection; Treat HCV infection
Regulatory Designation
PartnerEnanta Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today